Preductal MR 35 mg

Preductal MR 35 mg is a drug for angina pectoris, sometimes referred to by the brand name Preductal MR 35 mg. Each tablet contains 35 mg of Preductal MR 35 mg. Preductal MR 35 mg is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of fatty acid metabolism.

1 tablet of Preductal MR 35 mg twice daily during meals.

Renal Impairment: In patients with moderate renal impairment (creatinine clearance 30-60 mL/min), the recommended dose is 1 tablet Preductal MR 35 mg in the morning during breakfast.

Elderly: Elderly patients may have increased Preductal MR 35 mg exposure due to age-related decrease in renal function. In patients with moderate renal impairment (creatinine clearance 30-60 mL/min), the recommended dose is 1 tablet Preductal MR 35 mg in the morning during breakfast.

Dose titration in elderly patients should be exercised with caution.

Children: The safety and efficacy of Preductal MR 35 mg in children <18 years have not been established. No data are available.

Hypersensitivity to Preductal MR 35 mg or to any of the other ingredients of Preductal MR 35 mg. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome and other related movement disorders. Severe renal impairment (creatinine clearance <30 mL/min).

Use in lactation: Preductal MR 35 mg is generally not recommended during breastfeeding.

Preductal MR 35 mg is used for symptomatic treatment of stable angina (chest pain) as an additional therapy to other frontline medicines.

Sympatholytics, nifedipine, nitroglycerin, diuretics, hydralazine and other antihypertensive drugs potentiate hypotension.

Antiarrhythmic and anesthetic medications increase the risk of bradycardia, arrhythmia, hypotension.

Digitalis drugs potentiate slowing AV conduction.

Simultaneously intravenous injection of verapamil and diltiazem may cause cardiac arrest.

Beta-adrenoceptor agonists, aminophylline, cocaine, estrogens, indomethacin and other NSAIDs impair antihypertensive effect.

Preductal MR 35 mg Interhealthcare Pharmaceuticals enhances and prolongs the action of anti depolarizing muscle relaxants.

Combination with alcohol leads to mutual reinforcement of inhibitory effects on the CNS.

Allergens increased the risk of severe systemic allergic reactions or anaphylaxis.

Metoprolol edits the effectiveness of insulin and oral antidiabetic drugs and increases the risk of hypoglycemia.

Oral contraceptives, cimetidine, ranitidine, phenothiazines raise the level of this drug in the blood, rifampicin decreases it.

Preductal MR 35 mg Interhealthcare Pharmaceuticals reduces the clearance of lidocaine, the effectiveness of beta 2-agonists (it is necessary to increase the dose of the latter).

This medicine is incompatible with MAO inhibitors of type A.

Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. Headache, asthenia, or weakness may be noted as early and transient symptoms. However, significant adverse effects due to Methyldopa have been infrequent and this agent usually is well tolerated.

The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.

Cardiovascular: Aggravation of angina pectoris, congestive heart failure, prolonged carotid sinus hypersensitivity, orthostatic hypotension (decrease daily dosage), edema or weight gain, bradycardia.

Digestive: Pancreatitis, colitis, vomiting, diarrhea, sialadenitis, sore or "black" tongue, nausea, constipation, distension, flatus, dryness of mouth.

Endocrine: Hyperprolactinemia.

Hematologic: Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; positive tests for antinuclear antibody, LE cells, and rheumatoid factor, positive Coombs test.

Hepatic: Liver disorders including hepatitis, jaundice, abnormal liver function tests.

Hypersensitivity: Myocarditis, pericarditis, vasculitis, lupus-like syndrome, drug-related fever, eosinophilia.

Nervous System/Psychiatric: Parkinsonism, Bell’s palsy, decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, psychic disturbances including nightmares and reversible mild psychoses or depression, headache, sedation, asthenia or weakness, dizziness, light-headedness, paresthesias.

Metabolic: Rise in BUN.

Musculoskeletal: Arthralgia, with or without joint swelling; myalgia.

Respiratory: Nasal stuffiness.

Skin: Toxic epidermal necrolysis, rash.

Urogenital: Amenorrhea, breast enlargement, gynecomastia, lactation, impotence, decreased libido.

Preductal MR 35 mg is a drug for angina pectoris sold under the brand name Preductal MR 35 mg. Preductal MR 35 mg is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Preductal MR 35 mg is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart, which leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion.